Effects of canagliflozin on human myocardial redox signalling: clinical implications

AIMS: Recent clinical trials indicate that sodium-glucose cotransporter 2 (SGLT2) inhibitors improve cardiovascular outcomes in heart failure patients, but the underlying mechanisms remain unknown. We explored the direct effects of canagliflozin, an SGLT2 inhibitor with mild SGLT1 inhibitory effects...

Descripción completa

Detalles Bibliográficos
Autores principales: Kondo, Hidekazu, Akoumianakis, Ioannis, Badi, Ileana, Akawi, Nadia, Kotanidis, Christos P, Polkinghorne, Murray, Stadiotti, Ilaria, Sommariva, Elena, Antonopoulos, Alexios S, Carena, Maria C, Oikonomou, Evangelos K, Reus, Elsa Mauricio, Sayeed, Rana, Krasopoulos, George, Srivastava, Vivek, Farid, Shakil, Chuaiphichai, Surawee, Shirodaria, Cheerag, Channon, Keith M, Casadei, Barbara, Antoniades, Charalambos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Translational Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691807/
https://www.ncbi.nlm.nih.gov/pubmed/34293101
http://dx.doi.org/10.1093/eurheartj/ehab420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691807/
https://www.ncbi.nlm.nih.gov/pubmed/34293101
http://dx.doi.org/10.1093/eurheartj/ehab420

Ejemplares similares